Drobniewski was director of the UK Public Health Laboratory Service,National Mycobacterium (TB) Reference Laboratory from 1996 to 2015.[2] He was elected president of the European Society for Mycobacteriology from 2006 to 2007.[1] In 2006,he directed Health Sciences Research.[2] He was also the member and then Chair of the WHO European Laboratory initiative on TB,HIV and Viral Hepatitis,[4] and worked as a member of the WHO Global Strategic and Technical Advisory Group (STAG) in 2008.[5] He is a founding member of European Center for Disease Control (ECDC) European TB Reference Laboratory Network since 2009.[1] He has also held advisory and governance roles,including working as a member of the NICE Guideline Development Group for Tuberculosis,[6] member of the British Thoracic Society National Clinical MDR-TB Advisory Panel,[7] Trustee-Director of Peter Sowerby Foundation[8] and a NICE-TAC member.[9]
Research
Drobniewski's research focuses on microbiology,highlighting molecular diagnostics,drug resistance,and management of tuberculosis and respiratory infections. His work has investigated genotyping methods such as spoligotyping and variable number tandem repeats (VNTRs),[10] and has used whole genome sequencing (WGS) of TB strains in understanding of the evolution[11] and transmission of TB during outbreaks in multiple countries.[12] His work has identified associations between pathogengenotypes,drug resistance,[13] and lineage across different geographical population groups,[14] including patterns specific to the Beijing lineage.[15] In collaborative studies,he used whole-genome sequencing (WGS) to analyze TB drug resistance and transmission[16] and contributed to the development of non-microbiological genotypic-prediction of first line anti-TB drugs from cultured isolates,[17][18] and supported their use in routine diagnostic services.[19]
Drobniewski's work contributed to the understanding of within-host evolution in chronically ill patients and the role of compensatory mutations in bacterial fitness. He has evaluated the performance and reliability[20] of rapid detection methods like nucleic acid amplification and real-time PCR[21] His studies have also addressed other pathogens,including Bacillus cereus,and their involvement in severe infections[22] and foodborne illness.[23]
Drobniewski's studies have emphasized the need for improved treatment options for tuberculosis.[24]
Drobniewski, F. A.; Watterson, S. A.; Wilson, S. M.; Harris, G. S. (2000). "A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis". Journal of Medical Microbiology. 49 (3): 271–278. doi:10.1099/0022-1317-49-3-271. PMID10707947.
↑Nikolayevskyy, V.; Niemann, S.; Anthony, R.; van Soolingen, D.; Tagliani, E.; Ködmön, C.; van der Werf, M. J.; Cirillo, D. M. (November 2019). "Role and value of whole genome sequencing in studying tuberculosis transmission". Clinical Microbiology and Infection. 25 (11): 1377–1382. doi:10.1016/j.cmi.2019.03.022. PMID30980928.
↑Agaisse, H; Gominet, M; Okstad, O A; Kolstø, A B; Lereclus, D (1999). "PlcR is a pleiotropic regulator of extracellular virulence factor gene expression in Bacillus thuringiensis". Mol Microbiol. 32 (5): 1044. doi:10.1046/j.1365-2958.1999.01419.x. PMID10361306.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
